Top worldwide anti-rheumatics by revenue 2017 and 2024

This statistic displays the top anti-rheumatics worldwide by revenue in 2017 and a projection for 2024. Enbrel, a drug developed by Pfizer, Amgen, and Takeda, is expected to generate some four billion U.S. dollars in revenue in 2024. Anti-rheumatic drugs is used to treat and slow the progress of rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease that principlally attacks the joints but also impacts tissues and organs. Anti-rheumatic productsSome of the top anti-rheumatic products in the world include J&J, Merck & Co., and Mitsubishi’s Remicade, which generated 8.1 billion U.S. dollars in revenue in 2016 and is expected to decrease to 2.7 billion U.S. dollars by 2022. This drug accounted for over 15 percent of the global market in 2016. Remicade is a trade name for infliximab, an antibody used in the treatment of autoimmune diseases. It is marketed under the name Remicade in the United States and cost between 19,000 and 22,000 per year for patients. Merck & Co. markets this product as Schering-Plough in other regions. Merck & Co. generated 1.7 billion U.S. dollars in their oncology segment in 2016. Remicade works by targeting tumor necrosis factor alpha and inhibiting its activity, but unlike similar rheumatic products like Humira, it is a monoclonal antibody.Rheumatic diseases include conditions that affect the joints and connective tissue. Arthritis and gout are some of the more common types of this autoimmune disease. Osteoarthritis is one of the most common types of arthritis in the United States, it is characterized by the destruction of cartilage and bone. In Canada, 4.8 million adults over 15 reported that they had been diagnosed with arthritis.

本统计数据显示了2017年全球抗风湿药按收入排名的情况，并对2024年的市场进行了预测。由辉瑞、安进和田边三菱制药共同研发的恩利（Enbrel）预计在2024年将创造约四十亿美元的收益。抗风湿药主要用于治疗和延缓类风湿性关节炎的进展。类风湿性关节炎是一种主要侵袭关节但亦影响组织和器官的自身免疫性疾病。全球顶尖的抗风湿产品中包括强生（J&J）、默克公司（Merck & Co.）以及三菱制药的瑞麦德（Remicade），该产品在2016年创造了81亿美元的收益，预计到2022年将减少至27亿美元。该药物在2016年占据了全球市场的超过15%。瑞麦德是英夫利昔单抗的商标名，一种用于治疗自身免疫性疾病的单克隆抗体。在美国，瑞麦德以Remicade品牌销售，患者每年的费用在19,000至22,000美元之间。默克公司在其他地区将该产品命名为施文宁（Schering-Plough）。默克公司在2016年的肿瘤学领域创造了17亿美元的收益。瑞麦德通过靶向肿瘤坏死因子α并抑制其活性来发挥作用，但与类似的风湿药如修美乐（Humira）不同，它是一种单克隆抗体。风湿性疾病包括影响关节和结缔组织的疾病，关节炎和痛风是该类自身免疫疾病中较为常见的类型。骨关节炎是美国最常见的关节炎类型之一，其特征是软骨和骨的破坏。在加拿大，有4,800,000名15岁以上的成年人报告称他们已被诊断患有关节炎。